Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies

Česká verzia

Authors: J. Vítovec ¹; L. Špinarová ¹; J. Špinar ²
Authors place of work: I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny Brno – ICRC, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC ¹; Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jindřich Špinar, CSc., FESC ²
Published in the journal: Vnitř Lék 2012; 58(7 a 8): 228-233
Category: 60th Birthday prof. MUDr. Miroslav Souček, CSc.

Summary

The SHIFT study showed a positive effect of ivabradine in patients with chronic heart failure, sinus rhythm and heart rate at rest above 70 beats per minute. The aim of the first sub-study was to ascertain the effect of ivabradine on changes to the left ventricle function using echocardiography; ivabradine significantly increased ejection fraction of the left ventricle and reduced terminal left ventricular end-systolic and end-diastolic volumes. The second sub-study explored changes to the quality of life in patients treated with ivabradine or placebo. This study also showed statistically significantly improved quality of life after treatment with ivabradine. Both sub-studies confirmed the positive effect of ivabradine on patients with optimal treatment of heart failure, including maximum tolerated dose of beta-blockers and sinus heart rate above 70/min.

Key words:
ivabradine – echocardiography – quality of life – heart failure

Zdroje

1. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933–389.

2. Špinar J, Hradec J, Meluzín J et al. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor et Vasa 2007; 49: K5–K33.

3. Hradec J. Srdeční selhání – epidemie 21. století. Vnitř Lék 2004; 51 (Suppl 1): S23–S31.

4. Jhund PS, Macintyre K, Simpson CR et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119: 515–523.

5. Shafazand M, Schaufelberger M, Lappas G et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J 2009; 30: 671–678.

6. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003; 107: 1570–1575.

7. Udelson JE. Ventricular remodeling in heart failure and the effect of beta-blockade. Am J Cardiol 2004; 93: 43B–48B.

8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR//XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–2007.

9. Lechat P, Hulot JS, Escolano S et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–1433.

10. McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784–794.

11. Katz AM. The myocardium in congestive heart failure. Am J Cardiol 1989; 63: 12A–16A.

12. Diaz A, Bourassa MG, Guertin MC et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967–974.

13. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279–288.

14. Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006; 27: 65–75.

15. Komajda M, Follath F, Swedberg K et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure Survey programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464–474.

16. DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res 2006; 53: 399–406.

17. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf 2008; 31: 95–107.

18. Swedberg K, Komajda M, Bohm M et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled trial. Lancet 2010; 376: 875–885. Erratum in Lancet 2010; 376: 1988.

19. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling – concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569–582.

20. St John Sutton M, Pfeffer MA, Plappert T et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89: 68–75.

21. Solomon SD, Anavekar N, Skali H et al. Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738–3744.

22. St John Sutton M, Ghio S, Plappert T et al. REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation 2009; 120: 1858–1865.

23. Tardif JC, O’Meara E, Komajda M et al. SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 2011; 32: 2507–2515.

24. Kramer DG, Trikalinos TA, Kent DM et al. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010; 56: 392–406.

25. Juenger J, Schellberg D, Kraemer S et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002; 87: 235–241.

26. Soto GE, Jones P, Weintraub WS et al. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 2004; 110: 546–551.

27. Russell SD, McNeer FR, Higginbotham MB. Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. Am Heart J 1998; 135: 398–405.

28. Shah MR, Hasselblad V, Stinnett SS et al. Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. Eur J Heart Fail 2002; 4: 297–304.

29. Dobre D, van Jaarsveld CH, de Jongste MJ et al. The effect of beta-blocker therapy on quality of life in heart failure patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 2007; 16: 152–159.

30. Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med 1996; 334: 835–840.

31. Ekman I, Chassany O, Komajda M et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 2011; 32: 2395–2404.

32. Stanek EJ, Oates MB, McGhan WF et al. Preferences for treatment outcomes in patients with heart failure: symptoms versus. survival. J Card Fail 2000; 6: 225–232.

33. Lesman-Leegte I, Jaarsma T, Coyne JC et al. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age- and gender-matched community controls. J Card Fail 2009; 15: 17–23.

34. Ekman I, Kjörk E, Andersson B. Self-assessed symptoms in chronic heart failure – important information for clinical management. Eur J Heart Fail 2007; 9: 424–428.

35. Ekman I, Cleland JG, Swedberg K et al. Symptoms in patients with heart failure are prognostic predictors: insights from COMET. J Card Fail 2005; 11: 288–292.

36. Zuluaga MC, Guallar-Castillón P, López-Garcia E et al. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur J Heart Fail 2010; 12: 1372–1378.

37. DiFrancesco D, Camm AJ. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757–1765.

38. Camm J, Talajic M, Komajda M at al. Cardiac safety of selective heart rate reduction with ivabradine in chronic heart failure: Insights from the SHIFT ECG-Holter Sub-study. Eur J Heart Failure 2011; 10: (Suppl S1): S134.

39. Špinar J, Vítovec J, Hradec J et al. Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure 2011. Cor et Vasa 2012; 54: E113–E134.